FindTrial
Sign In

Evaluation of early treatment response and volumetric dose evaluation to target and organ at risk (small bowel/bladder/rectum) during radiation therapy of cervical cancer.

ASSESSMENT OF EARLY TREATMENT RESPONSE AND DOSIMETRIC EVALUATION IN LOCALLY ADVANCED CERVICAL CANCER TREATED WITH 3D CONFORMAL RADIATION THERAPY ALONG WITH CONCURRENT CISPLATIN AND IMAGE GUIDED HIGH DOSE RATE BRACHYTHERAPY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/03/040851
Enrollment
20
Registered
2022-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- GOOD Health Condition 2: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

None listed

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Biopsy proven carcinoma of cervix 2. Age : between 18-65 yrs 3. FIGO Stage IIB â?? IIIB 4. Karnofsky performance scale score 70 or above 5. Normal kidney, liver and bone marrow function 6. Patient who have given informed consent

Exclusion criteria

Exclusion criteria: 1. Early stage cancer FIGO stage IA â??IIA 2. Metastatic patients 3. Lack of Histo-pathological proof of malignancy 4. Doubtful follow-up and /or non-compliance 5. Uncontrolled co-morbid conditions e.g. Hypertension, Diabetes Mellitus, Chronic Obstructive pulmonary disease (COPD), coronary artery disease (CAD), Severe Mental or Physical Disorder 6. Pregnancy 7. Deranged renal, liver function test 8. Patient refusing to give written informed consent 9. H/O- of previous irradiation 10. H/O-of allergy 11. Collagen vascular disease

Design outcomes

Primary

MeasureTime frame
a) To evaluate early treatment response in locally advanced cervical cancer treated with 3D conformal radiotherapy and image based brachytherapy b) To evaluate volumetric doses to target and OAR (rectum/bladder/small bowel) Timepoint: 1O MONTHS—

Secondary

MeasureTime frame
a) To evaluate acute haematological/bladder/bowel toxicities. b) To compare dosimetric parameter between 3D conformal radiation therapy and Volumetric Modulated Arc Therapy (VMAT) Timepoint: 10 MONTHS—

Countries

India

Contacts

Public ContactDR ANU AGRAWAL

AIIMS

drspathy@gmail.com01129575243

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026